China is preparing to steal the jobs of the future
Sometimes referred to as the 'singularity', it's long been the stuff of science fiction, but many techies believe, such is the pace of current development, that it is on the verge of becoming a reality.
Whoever gets there first, it is widely believed, will inherit the Earth, embedding their influence, ideology and systems of governance into world affairs for generations to come.
It's a frightening as well as awe-inspiring prospect and it is one whose potentially transformational geopolitical consequences are only now starting to be more widely appreciated.
And it's why the US and China are increasingly engaged in what can only be described as a new arms race – or space race – to develop and harness artificial superintelligence for economic and geopolitical superiority. In both jurisdictions, hundreds of billions of dollars a year are being poured into getting there first.
Yet though the Trump administration is only too aware of the threat, its response is oddly backward-looking and counterproductive. Despite the apparent world lead the US has in supercomputing, there is a high chance it will end up losing the war.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
‘One-two-punch' cancer vaccine weaponises the immune system to attack ANY tumour – raising hopes of universal jab
A NEW experimental cancer jab could one day be used to fight any type of tumour, US scientists claim. Experts from the University of Florida say they've developed a powerful mRNA vaccine that trains the immune system to target and destroy cancer cells. 1 It's dubbed the 'one-two punch' after the powerful boxing move where a jab sets up a cross to knock the opponent down. This is because this jab also works in two steps: first by waking up the immune system, then helping it attack cancer cells more effectively. It does this by boosting the effects of immunotherapy, a type of cancer treatment that helps the immune system recognise and attack cancer cells. The groundbreaking discovery brings us closer to a universal cancer jab that could work across many tumour types, it is hope Research in mice showed that combining the jab with a common immunotherapy drug called an immune checkpoint inhibitor helped fight even resistant tumours. Dr Elias Sayour, the study's senior author, said: 'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumour or virus, so long as it is an mRNA vaccine, could lead to tumour-specific effects.' He added: 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccines to sensitise the immune system against a patient's individual tumour.' Unlike previous cancer vaccines that try to hone in on a particular protein in the cell, the new jab works by simply firing up the immune system, tricking it into responding as if it were under viral attack. By boosting levels of a protein called PD-L1 inside tumours, it makes them more receptive to immunotherapy and helps immune cells recognise them as dangerous. Lead scientist Dr Duane Mitchell, co-author of the study, said: 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. The signs and symptoms of cancer 'And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine.' For the past eight years, Dr Sayour's lab has been developing cutting-edge vaccines using the same mRNA technology found in Covid jabs. Last year, they trialled a personalised version in four patients with glioblastoma - an aggressive and usually deadly brain tumour. They saw a fast and fierce immune response that helped fight off the cancer. 'Profound' The latest study, published today in Nature Biomedical Engineering, tested a more generalised version of the jab, not tailored to individual tumours, and still saw dramatic results. In mice with melanoma, a type of deadly skin cancer, combining the jab with an immunotherapy drug called a PD-1 inhibitor led to tumour shrinkage While in some skin, bone, and brain cancer models, the jab alone eliminated tumours completely. Dr Sayour explained: 'Even an immune response that is seemingly unrelated to the cancer may be able to activate T cells that weren't working before, allowing them to multiply and kill the tumour if the response is strong enough.' Dr Mitchell said: 'It could potentially be a universal way of waking up a patient's own immune response to cancer. 'And that would be profound if generalisable to human studies.' The team are now working to improve the formula and begin human trials as soon as possible. Cancer treatments explained – from chemotherapy to radiotherapy and surgery Because everybody is different and people's cancers are caught at different stages, there is no one size fits all treatment. It's also common for patients to be offered a combination of treatments to provide the best chance of survival. According to the NHS, there are six main ways of treating cancer. Surgery: Removes the tumour physically; not used for cancers like blood or lymphatic system tumours. Radiotherapy: Uses high-energy rays (like X-rays) to destroy cancer cells and shrink tumours. Nearly half of cancer patients receive this. Common side effects include fatigue and sore skin. Chemotherapy: Systemic treatment with powerful drugs that kill fast-dividing cells throughout the body. May be given before or after surgery to shrink tumours or reduce recurrence risk. Side effects range from hair loss to nausea. Hormonal therapy: Stops certain cancers (like breast or prostate) from growing by blocking hormone production or function. Targeted/biological therapy: Focuses on specific cancer-linked proteins or genetic changes; also includes some immunotherapy drugs. Stem cell/bone marrow transplant – Replaces damaged blood-forming cells after high-dose chemotherapy or radiotherapy; used in cancers like lymphoma, leukemia and myeloma.
Reuters
2 hours ago
- Reuters
China's Unitree Robotics starts IPO process
BEIJING, July 18 (Reuters) - Chinese startup Unitree Robotics has begun the so-called "tutoring" process for a potential initial public offering, a filing with the securities regulator showed on Friday. CITIC Securities acts as the company's tutoring institution and is scheduled to assist Unitree in preparing the listing application documents in accordance with relevant regulations in the fourth quarter of this year.
Auto Express
2 hours ago
- Auto Express
The Chinese car explosion continues as yet another new brand arrives in the UK
UK distributor Jameel Motors and Chinese giant GAC (Guangzhou Automobile Group) have signed a joint venture to bring several new cars to the UK market, including a hatchback and an SUV. The first two cars, the AION V SUV and the AION UT hatchback, are both fully-electric and have already been revealed for other markets so we already know plenty when it comes to their design and technical make up. Jameel Motors, the firm tasked with distributing GAC's offerings in the UK, already works with Farizon Auto in the electric van segment. The GAC cars, however, will be the first passenger vehicles Jameel Motors will have dealt with here. Jameel Motors also says 'Additional models will follow to expand the AION line-up' with first customer deliveries of the AION V and AION UT expected by spring 2026. Advertisement - Article continues below Speaking on the new venture with Jameel Motors, Wayne Wei, President of GAC International, added: 'GAC's entry into the UK marks a crucial step in its internationalisation strategy. As we set foot in this dynamic market, GAC is committed to bringing industry-leading products and first-class services to UK consumers.' The AION UT hatchback will provide a new rival to the likes of the Volkswagen ID.3, Kia EV3 and MG4 when it arrives. In other markets the AION UT is offered with a 50kWh battery or a larger 60kWh unit that can up maximum range from 210 miles to 310 miles (though this is from China's more lenient CLTC testing scheme). Two electric motor versions are offered - a 134bhp or a 201bhp model with both sending power to the front wheels. The AION V is aimed at the Renault Scenic and Skoda Enyaq as a C-segment SUV. Sitting on GAC AEP 3.0 platform, it actually shares its underpinnings with the Chinese-built Toyota bZ3X and comes with several battery sizes ranging from 62kWh to 90kWh - the latter of which can provide a range of 382 miles (WLTP). It's front-wheel drive only with either a 134bhp or a 221bhp motor. Full UK specifications and pricing for GAC's new cars will be made available later in the year as the cars near a UK launch. Our dealer network has 1,000s of great value new cars in stock and available now right across the UK. Find your new car… Find a car with the experts New Xiaomi YU7 2025 review: a world-beating new EV to worry the establishment New Xiaomi YU7 2025 review: a world-beating new EV to worry the establishment BMW or Mercedes would do anything to keep the new Xiaomi YU7 from sale in the UK and Europe, and this is why Electric Car Grant in detail: Which cars will get the UK EV discount? Electric Car Grant in detail: Which cars will get the UK EV discount? The government has set out its plan to help reduce the cost of affordable EVs by introducing a new £3,750 Electric Car Grant for new EVs sold under £3… Electric Mercedes CLA Shooting Brake will keep going long after rivals need to stop Electric Mercedes CLA Shooting Brake will keep going long after rivals need to stop The second of Merc's new-era EVs is here in the form of an attractive estate with a huge range
